Element Biosciences won a court order in a German patent lawsuit against Illumina, requiring Illumina to recall infringing sequencing systems and reagent kits from commercial customers. Element said the court order covers products put into circulation since March 31, 2023. The case underlines how IP enforcement can directly disrupt deployed lab workflows and procurement timelines. For sequencing and diagnostic developers, the remedy—recall of systems and kits—raises the commercial and operational risk of patent infringement findings during active customer use. For biotech labs and partners, the decision also increases pressure on vendors to validate patent clearance across instrument and reagent supply chains, not just core hardware.